NeoTherapeutics Inc.: The Newport Beach drug development...

NeoTherapeutics Inc.: The Newport Beach drug development company, which completed its initial public offering Sept. 26, reported a third-quarter net loss of $260,047, or 9 cents a share, compared with a year earlier net loss of $92,307, or 4 cents a share. The company had no revenue for the quarter, compared with revenue of $29,318 from grants a year ago. For the first nine months, the company posted a loss of $530,746, or 22 cents a share, compared with a net loss of $203,860, or 10 cents a share, for the first three quarters a year ago. The company had no revenue, compared with revenue of $124,171 for the same period last year. The company said the increase in its net loss was principally due to indirect expenses related to the company’s recent equity financing and a decrease in grant revenue.